We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Xolair Qui Tam Dismissal Affirmed By 1st Circuit, But State Claims Remanded

Mealey's (June 20, 2016, 2:27 PM EDT) -- BOSTON — The First Circuit U.S. Court of Appeals on June 17 affirmed dismissal without prejudice of two relators’ claims that Novartis Pharmaceuticals Corp. and Genentech Inc. marketed the asthma drug...
To view the full article, register now.